about
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.Alpha-fetoprotein elevation in NUT midline carcinoma: a case reportPARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaGemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of boneSuccessful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report.Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma.Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activityGingival metastasis of a radiotherapy-induced breast angiosarcoma: diagnosis and multidisciplinary treatment achieving a prolonged complete remission.Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.Adoptive immunotherapy against sarcomas.Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.Trabectedin clinical cases: use according to indication in diverse clinical scenarios.Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.Painful pathologic fracture of the humerus: percutaneous osteoplasty with bone marrow nails under hybrid computed tomography and fluoroscopic guidance.Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study().Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.Activity of cytokine-induced killer cells against bone and soft tissue sarcoma.An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient.Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma.Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
P50
Q33419286-32472868-31C3-4195-ADBA-A139B8D976F8Q33560408-9510358E-89BB-48DA-85B9-228A588D32C2Q33617922-8B8E1BCA-20C0-473F-A35C-7EEF893D03D4Q34039279-B06E365D-2F49-448F-A616-D74CD540E163Q34085052-B77FBD53-49AE-4690-AD8E-F0F5BA2DA24EQ35599789-5CD993CC-CD32-46A4-B309-3EA5AD27D99EQ35995283-72EBDF69-48D5-47ED-9CCD-3392A5CE6E3FQ36161839-CF092A20-2816-427D-AB73-1EAE11453227Q36670859-A85C4205-018D-4A22-9F5B-B9D80320C086Q36871777-E997CF36-1F46-4518-8DBD-1E54C3330F4EQ38034368-24DDEFF1-DB3E-4287-8023-CC7199C29FC4Q38168851-0A2EA68F-6038-4398-A01D-23E607720A28Q38291193-D4074D0F-72A2-4435-834F-D8970B064981Q38386665-8C27D5B4-0510-463C-B5FD-4B6976781AB2Q38515915-F1B0212E-AE9C-4728-8C3D-973A68972268Q38975629-A6B04167-DCA7-47AD-B5F5-0FC2E7EEA195Q39041744-24E4D181-306B-44CC-983F-1EC3E99C8056Q39191957-40CDBA94-8798-4EAD-865B-26C54F69BB53Q39263570-7F4D984F-D5BD-46B3-8633-03118C2DF023Q39444949-23B69A5C-7819-4D63-BDFB-6733D915E347Q40225231-1EB8EFAF-F03D-4A0D-9754-FC1A71CA937EQ42274903-E6CD6C5F-DC3D-4542-A944-8438BABE579BQ42729198-CE87F31F-9CB8-4D8B-B475-602838E25295Q43231637-62F3C96D-0139-4D2A-804D-865E57D56240Q44382222-F798F635-C2D8-463B-AE55-B41800553713Q44481728-BBCF1BEF-E49D-4906-A016-CAC70CDCA23AQ47583458-B01B83C4-6A92-46C3-82EE-C27AAE498FFEQ47792575-CA8A4B4C-ED1E-42B2-BF47-C65340F73C54Q48280684-DBC8C498-DB18-4D91-8593-CD1B47909411Q48540902-90A58818-B477-497E-A0B8-BA4D655D0FDEQ48883380-2C891E4D-3567-4D4F-BFA3-6B7C63964ECFQ49918667-00E5BB4C-B425-4BEA-8181-E58965A0E990Q51107291-CEECB7F8-3E96-47B8-BDED-D75B494EDDFAQ51694181-B58F2E5C-B455-4908-AE03-4AF62E2E6BE6Q51802610-08334B04-9B28-45E3-99C1-93C79717A352Q52658441-18BBE038-F77C-4F25-BD02-A3A5145C0F90Q52665713-5964557C-3A61-4A7A-8821-693DEF805489Q52714322-6C96EC72-63A1-4904-B8EB-3A4A487A8355Q52737237-79D687B5-1C48-4F8E-977F-B68E01EC9E47Q53090977-B5C778F0-9351-4A91-A47B-DC0C246AB06F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni Grignani
@ast
Giovanni Grignani
@en
Giovanni Grignani
@es
Giovanni Grignani
@nl
type
label
Giovanni Grignani
@ast
Giovanni Grignani
@en
Giovanni Grignani
@es
Giovanni Grignani
@nl
prefLabel
Giovanni Grignani
@ast
Giovanni Grignani
@en
Giovanni Grignani
@es
Giovanni Grignani
@nl
P106
P21
P31
P496
0000-0001-5515-569X